Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstroms Macroglobulinemia: A Multicenter Trial of the European Myeloma Network.

Trial Profile

Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstroms Macroglobulinemia: A Multicenter Trial of the European Myeloma Network.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2015

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Rituximab (Primary)
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Acronyms BDR-WM
  • Most Recent Events

    • 17 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Jun 2012 Planned number of patients changed from 61 to 90 as reported by European Clinical Trials Database record.
    • 24 Feb 2011 Planned end date changed from 1 Jan 2011 to 1 Dec 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top